Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Phase 4
Terminated
- Conditions
- High Altitude Pulmonary Edema
- Interventions
- Drug: Placebo
- Registration Number
- NCT03490916
- Lead Sponsor
- Vincent Kan
- Brief Summary
The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- At least 18 years of age
- Able to consent
- English speaking
- Trekking directly to Everest Base Camp
Exclusion Criteria
- Age less than 18 years
- Non-English speaking
- Pregnant
- Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
- Been on a high-altitude trek 2 weeks prior to this study
- Has taken acetazolamide 1 week prior to start of trek
- Has a sulfa allergy
- Has any type of acute or chronic pulmonary conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Acetazolamide normal dose Acetazolamide One (1) dose of 250mg of Acetazolamide Placebo Placebo One (1) dose of placebo
- Primary Outcome Measures
Name Time Method Pulmonary Edema Before and After Taking Acetazolamide 1 month Edema measured through ultrasound exam
- Secondary Outcome Measures
Name Time Method Time to Completion of Ultrasound Exams 1 month Time it takes to complete ultrasound exams
Trial Locations
- Locations (1)
UMass Medical School
🇺🇸Worcester, Massachusetts, United States